Phio Pharmaceuticals Corp (PHIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,003 | -8,698 | -6,327 | -3,935 | -1,769 |
| Depreciation Amortization | 1 | 3 | 2 | N/A | N/A |
| Accounts payable and accrued liabilities | -175 | 183 | 263 | -18 | 174 |
| Other Working Capital | -316 | 235 | 218 | 26 | 451 |
| Other Operating Activity | 490 | 298 | -56 | 112 | -131 |
| Operating Cash Flow | $-4,003 | $-7,979 | $-5,900 | $-3,815 | $-1,275 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 3 | -12 | -12 | -5 | -2 |
| Investing Cash Flow | $3 | $-12 | $-12 | $-5 | $-2 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 2,680 |
| Common Stock Issued | N/A | 23,670 | 11,265 | 9,213 | 6,493 |
| Other Financing Activity | 0 | -30 | -30 | 0 | 0 |
| Financing Cash Flow | $N/A | $23,640 | $11,235 | $9,213 | $9,173 |
| Beginning Cash Position | 21,031 | 5,382 | 5,382 | 5,382 | 5,382 |
| End Cash Position | 17,031 | 21,031 | 10,705 | 10,775 | 13,278 |
| Net Cash Flow | $-4,000 | $15,649 | $5,323 | $5,393 | $7,896 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,003 | -7,979 | -5,900 | -3,815 | -1,275 |
| Capital Expenditure | N/A | -12 | -12 | -5 | -2 |
| Free Cash Flow | -4,003 | -7,991 | -5,912 | -3,820 | -1,277 |